|
1
|
Pflug BR, Pecher SM, Brink AW, Nelson JB
and Foster BA: Increased fatty acid synthase expression and
activity during progression of prostate cancer in the TRAMP model.
Prostate. 57:245–254. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Klein EA, Cooperberg MR, Magi-Galluzzi C,
Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis
AC, Cherbavaz DS, et al: A 17-gene assay to predict prostate cancer
aggressiveness in the context of Gleason grade heterogeneity, tumor
multifocality, and biopsy undersampling. Eur Urol. 66:550–560.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Feldman BJ and Feldman D: The development
of androgen-independent prostate cancer. Nat Rev Cancer. 1:34–45.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Best CJ, Gillespie JW, Yi Y, Chandramouli
GV, Perlmutter MA, Gathright Y, Erickson HS, Georgevich L, Tangrea
MA, Duray PH, et al: Molecular alterations in primary prostate
cancer after androgen ablation therapy. Clin Cancer Res.
11:6823–6834. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Valencia-Sanchez MA, Liu J, Hannon GJ and
Parker R: Control of translation and mRNA degradation by miRNAs and
siRNAs. Genes Dev. 20:515–524. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ventura A and Jacks T: MicroRNAs and
cancer: Short RNAs go a long way. Cell. 136:586–591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Iorio MV and Croce CM: MicroRNAs in
cancer: Small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Baranwal S and Alahari SK: miRNA control
of tumour cell invasion and metastasis. Int J Cancer.
126:1283–1290. 2010.PubMed/NCBI
|
|
10
|
Bandrés E, Cubedo E, Agirre X, Malumbres
R, Zárate R, Ramirez N, Abajo A, Navarro A, Moreno I, Monzó M and
García-Foncillas J: Identification by Real-time PCR of 13 mature
microRNAs differentially expressed in colorectal cancer and
non-tumoural tissues. Mol Cancer. 5:292006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lowery AJ, Miller N, Devaney A, McNeill
RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G and
Kerin MJ: MicroRNA signatures predict oestrogen receptor,
progesterone receptor and HER2/neu receptor status in breast
cancer. Breast Cancer Res. 11:R272009. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bhattacharya A, Ziebarth JD and Cui Y:
Systematic analysis of microRNA targeting impacted by small
insertions and deletions in human genome. PLoS One. 7:e461762012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hebenstreit D, Wirnsberger G, Horejs-Hoeck
J and Duschl A: Signaling mechanisms, interaction partners and
target genes of STAT6. Cytokine Growth Factor Rev. 17:173–188.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rothstein TL: Inducible resistance to
Fas-mediated apoptosis in B cells. Cell Res. 10:245–266. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ansel KM, Djuretic I, Tanasa B and Rao A:
Regulation of Th2 differentiation and Il4 locus accessibility. Annu
Rev Immunol. 24:607–656. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ni Z, Lou W, Lee SO, Dhir R, DeMiguel F,
Grandis JR and Gao AC: Selective activation of members of the
signal transducers and activators of transcription family in
prostate carcinoma. J Urol. 167:1859–1862. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li BH, Yang XZ, Li PD, Yuan Q, Liu XH,
Yuan J and Zhang WJ: IL-4/Stat6 activities correlate with apoptosis
and metastasis in colon cancer cells. Biochem Biophys Res Commun.
369:554–560. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Benekli M, Baer MR, Baumann H and Wetzler
M: Signal transducer and activator of transcription proteins in
leukemias. Blood. 101:2940–2954. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Skinnider BF, Elia AJ, Gascoyne RD,
Patterson B, Trumper L, Kapp U and Mak TW: Signal transducer and
activator of transcription 6 is frequently activated in Hodgkin and
Reed-Sternberg cells of Hodgkin lymphoma. Blood. 99:618–626. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guiter C, Dusanter-Fourt I, Copie-Bergman
C, Boulland ML, Le Gouvello S, Gaulard P, Leroy K and Castellano F:
Constitutive STAT6 activation in primary mediastinal large B-cell
lymphoma. Blood. 104:543–549. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Melzner I, Bucur AJ, Brüderlein S, Dorsch
K, Hasel C, Barth TF, Leithäuser F and Möller P: Biallelic mutation
of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action
in the MedB-1 mediastinal lymphoma line. Blood. 105:2535–2542.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bruns HA and Kaplan MH: The role of
constitutively active Stat6 in leukemia and lymphoma. Crit Rev
Oncol Hematol. 57:245–253. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu L, Tan AC, Naiman DQ, Geman D and
Winslow RL: Robust prostate cancer marker genes emerge from direct
integration of inter-study microarray data. Bioinformatics.
21:3905–3911. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lin CH, Jackson AL, Guo J, Linsley PS and
Eisenman RN: Myc-regulated microRNAs attenuate embryonic stem cell
differentiation. EMBO J. 28:3157–3170. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nagel R, le Sage C, Diosdado B, van der
Waal M, Oude Vrielink JA, Bolijn A, Meijer GA and Agami R:
Regulation of the adenomatous polyposis coli gene by the miR-135
family in colorectal cancer. Cancer Res. 68:5795–5802. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu CJ, Tsai MM, Hung PS, Kao SY, Liu TY,
Wu KJ, Chiou SH, Lin SC and Chang KW: miR-31 ablates expression of
the HIF regulatory factor FIH to activate the HIF pathway in head
and neck carcinoma. Cancer Res. 70:1635–1644. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tong AW, Fulgham P, Jay C, Chen P, Khalil
I, Liu S, Senzer N, Eklund AC, Han J and Nemunaitis J: MicroRNA
profile analysis of human prostate cancers. Cancer Gene Ther.
16:206–216. 2009.PubMed/NCBI
|
|
28
|
Östling P, Leivonen SK, Aakula A, Kohonen
P, Mäkelä R, Hagman Z, Edsjö A, Kangaspeska S, Edgren H, Nicorici
D, et al: Systematic analysis of microRNAs targeting the androgen
receptor in prostate cancer cells. Cancer Res. 71:1956–1967. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Scapoli L, Palmieri A, Lo Muzio L,
Pezzetti F, Rubini C, Girardi A, Farinella F, Mazzotta M and
Carinci F: MicroRNA expression profiling of oral carcinoma
identifies new markers of tumour progression. Int J Immunopathol
Pharmacol. 23:1229–1234. 2010.PubMed/NCBI
|
|
30
|
Kanaan Z, Rai SN, Eichenberger MR, Roberts
H, Keskey B, Pan J and Galandiuk S: Plasma miR-21: A potential
diagnostic marker of colorectal cancer. Ann Surg. 256:544–551.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gaedcke J, Grade M, Camps J, Søkilde R,
Kaczkowski B, Schetter AJ, Difilippantonio MJ, Harris CC, Ghadimi
BM, Møller S, et al: The rectal cancer microRNAome-microRNA
expression in rectal cancer and matched normal mucosa. Clin Cancer
Res. 18:4919–4930. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xu XM, Qian JC, Deng ZL, Cai Z, Tang T,
Wang P, Zhang KH and Cai JP: Expression of miR-21, miR-31, miR-96
and miR-135b is correlated with the clinical parameters of
colorectal cancer. Oncol Lett. 4:339–345. 2012.PubMed/NCBI
|
|
33
|
Ma L and Weinberg RA: Micromanagers of
malignancy: Role of microRNAs inregulating metastasis. Trends
Genet. 24:448–456. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Khew-Goodall Y and Goodall GJ:
Myc-modulated miR-9 makes more metastases. Nat Cell Biol.
12:209–211. 2010.PubMed/NCBI
|
|
35
|
Pang Y, Young CY and Yuan H: MicroRNAs and
prostate cancer. Acta Biochim Biophys Sin (Shanghai). 42:363–369.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lin SL, Chiang A, Chang D and Ying SY:
Loss of mir-146a function in hormone-refractory prostate cancer.
RNA. 14:417–424. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Calò V, Migliavacca M, Bazan V, Macaluso
M, Buscemi M, Gebbia N and Russo A: STAT proteins: From normal
control of cellular events to tumorigenesis. J Cell Physiol.
197:157–168. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Schindler C and Darnell JE Jr:
Transcriptional responses to polypeptide ligands: The JAK-STAT
pathway. Annu Rev Biochem. 64:621–651. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Darnell JE Jr: STATs and gene regulation.
Science. 277:1630–1635. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Das S, Roth CP, Wasson LM and Vishwanatha
JK: Signal transducer and activator of transcription-6 (STAT6) is a
constitutively expressed survival factor in human prostate cancer.
Prostate. 67:1550–1564. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fukuda K, Fujitsu Y, Kumagai N and Nishida
T: Characterization of the interleukin-4 receptor complex in human
corneal fibroblasts. Invest Ophthalmol Vis Sci. 43:183–188.
2002.PubMed/NCBI
|
|
42
|
Ostrand-Rosenberg S, Grusby MJ and
Clements VK: Cutting edge: STAT6-deficient mice have enhanced
tumour immunity to primary and metastatic mammary carcinoma. J
Immunol. 165:6015–6019. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ostrand-Rosenberg S, Sinha P, Clements V,
Dissanayake SI, Miller S, Davis C and Danna E: Signal transducer
and activator of transcription 6 (Stat6) and CD1: Inhibitors of
immunosurveillance against primary tumours and metastatic disease.
Cancer Immunol Immunother. 53:86–91. 2004. View Article : Google Scholar : PubMed/NCBI
|
